BiotechTube

ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapy

Phase 2Active
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Refractory Aggressive B-cell Lymphomas

Conditions

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos, Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma, Nos, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, Grade 3b Follicular Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma

Trial Timeline

Mar 1, 2023 → Mar 1, 2029

NCT ID
NCT05583149

About ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapy

ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapy is a phase 2 stage product being developed by Johnson & Johnson for Refractory Aggressive B-cell Lymphomas. The current trial status is active. This product is registered under clinical trial identifier NCT05583149. Target conditions include Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05583149Phase 2Active

Competing Products

20 competing products in Refractory Aggressive B-cell Lymphomas

See all competitors
ProductCompanyStageHype Score
Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomideEli LillyPhase 1/2
41
agenT-797MiNK TherapeuticsPhase 1
25
eFT508 + AvelumabeFFECTOR TherapeuticsPhase 2
44
CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab)CelltrionPhase 3
77
Valemetostat TosylateDaiichi SankyoPhase 2
52
EnzalutamideAstellas PharmaPhase 2
52
ASP1650Astellas PharmaPhase 2
52
YM598Astellas PharmaPhase 2
52
erlotinib + etoposideAstellas PharmaPhase 2
52
Mitoxantrone Hydrochloride Liposome & EnlonstobartSun PharmaceuticalPhase 1/2
41
Lenvatinib + EverolimusEisaiPhase 1/2
41
perampanel + perampanel + perampanel + PlaceboEisaiPhase 3
77
Eribulin mesilate + Irinotecan hydrochlorideEisaiPhase 1/2
41
perampanelEisaiPhase 2
52
rabeprazole sodiumEisaiPre-clinical
23
LenvatinibEisaiPhase 2
52
E2007 (perampanel) + E2007 (perampanel) + PlaceboEisaiPhase 3
77
E2007 (perampanel) + E2007 (perampanel) + PlaceboEisaiPhase 3
77
TazemetostatEisaiPhase 2
52
RufinamideEisaiPhase 3
77

Other Products from Johnson & Johnson

Fentanyl transdermal therapeutic systemApproved
85
Nicotine Gum + Nicotine PatchApproved
85
galantamineApproved
85
IbrutinibApproved
85
Paliperidone ERApproved
85